{"id":"benzbromaron","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Eyes absent homolog 2, Eyes absent homolog 3, ATP-binding cassette sub-family G member 2"},"_scrapedAt":"2026-03-28T00:28:20.943Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Gout","diseaseId":"gout","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Hyperuricemia","diseaseId":"hyperuricemia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06966635","phase":"PHASE4","title":"Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets","status":"RECRUITING","sponsor":"Huashan Hospital","startDate":"2024-04-10","conditions":"Hyperuricemia or Gout, Nephrolithiasis","enrollment":312},{"nctId":"NCT05504083","phase":"PHASE2","title":"Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients","status":"COMPLETED","sponsor":"InventisBio Co., Ltd","startDate":"2022-09-28","conditions":"Hyperuricemia","enrollment":121},{"nctId":"NCT06582654","phase":"","title":"Normalizing Antibody Detection in First-void Urine","status":"RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2023-12-07","conditions":"Human Papillomavirus Infection","enrollment":150},{"nctId":"NCT05210517","phase":"PHASE4","title":"SGLT2 Inhibition: Uric Acid Excretion Study","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2020-10-01","conditions":"Type 2 Diabetes","enrollment":10},{"nctId":"NCT04213534","phase":"","title":"The Influence of Urate-lowering Therapy on Sperm Quality of Male Gouty Patients：A Prospective Cohort Study","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2020-10-10","conditions":"Gout","enrollment":60},{"nctId":"NCT03534037","phase":"PHASE4","title":"Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction","status":"UNKNOWN","sponsor":"National Defense Medical Center, Taiwan","startDate":"2020-02-01","conditions":"Hyperuricemia, Metabolic Syndrome, Left Ventricular Diastolic Dysfunction","enrollment":120},{"nctId":"NCT03185793","phase":"PHASE2","title":"Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-07-20","conditions":"Hyperuricemia","enrollment":198},{"nctId":"NCT02338323","phase":"NA","title":"Compare the Renal Protective Effects of Febuxostat and Benzbromarone","status":"COMPLETED","sponsor":"Shanghai 10th People's Hospital","startDate":"2015-01","conditions":"Chronic Kidney Disease, Hyperuricemia, Abnormal Renal Function","enrollment":160},{"nctId":"NCT03100318","phase":"PHASE3","title":"Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout","status":"COMPLETED","sponsor":"Fuji Yakuhin Co., Ltd.","startDate":"2017-04-01","conditions":"Hyperuricemia With or Without Gout","enrollment":201},{"nctId":"NCT02790450","phase":"PHASE2","title":"Acute Effects of Benzbromaron on the Pulmonary Circulation","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2015-10","conditions":"Idiopathic Pulmonary Arterial Hypertension","enrollment":10},{"nctId":"NCT02944214","phase":"NA","title":"Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients","status":"UNKNOWN","sponsor":"Shanghai 10th People's Hospital","startDate":"2016-10","conditions":"Chronic Kidney Disease, Hyperuricemia, Abnormal Renal Function","enrollment":800},{"nctId":"NCT02317861","phase":"PHASE1, PHASE2","title":"A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12","conditions":"Gout and Asymptomatic Hyperuricemia","enrollment":110},{"nctId":"NCT00422318","phase":"PHASE4","title":"Treatment of Hyperuricemia in Patients With Heart Failure","status":"COMPLETED","sponsor":"Tottori University Hospital","startDate":"2004-01","conditions":"Heart Failure, Hyperuricemia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":12,"therapeuticAreas":["Ophthalmology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Benzbromaron","genericName":"Benzbromaron","companyName":"Amsterdam UMC, location VUmc","companyId":"amsterdam-umc-location-vumc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}